Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-analysis

AIDS

Volumn 26, Issue 16, 2012, Pages 2039-2052

  Nachega, Jean B ^a,b   Uthman, Olalekan A ^b,c   Anderson, Jean ^d   Peltzer, Karl ^e,f   Wampold, Sarah ^a   Cotton, Mark F ^b,g   Mills, Edward J ^h   Ho, Yuh Shan ⁱ   Stringer, Jeffrey S A ^j,k   McIntyre, James A ^l,m   Mofenson, Lynne M ⁿ  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c KEELE UNIVERSITY   (United Kingdom)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e HUMAN SCIENCES RESEARCH COUNCIL   (South Africa)

^f UNIVERSITY OF THE FREE STATE   (South Africa)

^g STELLENBOSCH UNIVERSITY   (South Africa)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ ASIA UNIVERSITY   (Taiwan)

^j Centre for Infectious Disease Research   (Zambia)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l ANOVA HEALTH INSTITUTE   (South Africa)

^m UNIVERSITY OF CAPE TOWN   (South Africa)

ⁿ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

adherence; antiretroviral therapy; HIV infection; pregnancy; prevention of mother to child HIV transmission

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; DEVELOPED COUNTRY; DEVELOPING COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; META ANALYSIS; PATIENT COMPLIANCE; PERINATAL PERIOD; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE; SOCIOECONOMICS; SYSTEMATIC REVIEW; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; HIV SEROPOSITIVITY; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MEDICATION ADHERENCE; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SOCIAL CLASS; UNITED STATES;

EID: 84867746581     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328359590f     Document Type: Article

References (101)

1. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector, progress report 2010. Geneva, Switzerland: World Health Organization; 2010.
2. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-981.
3. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-1182.
4. Wiktor SZ, Ekpini E, Nduati RW. Prevention of mother-to-child transmission of HIV-1 in Africa. AIDS 1997; 11 (Suppl B): S79-S87.
5. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach: 2010 version. Geneva, Switzerland: World Health Organization; 2010.
6. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Progress report 2011. Geneva: Switzerland: World Health Organization; 2011.
7. World Health Organization. Countdown to zero: global plan for the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva, Switzerland: World Health Organization; 2011.
8. Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets 2011; 11:167-174.
9. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
10. Kobin AB, Sheth NU. Levels of adherence required for vir-ologic suppression among newer antiretroviral medications. Ann Pharmacother 2011; 45:372-379.
11. Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263-1268.
12. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse trans-criptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573.
13. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
14. Kaiser R, Bunnell R, Hightower A, Kim AA, Cherutich P, Mwangi M, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. PLoS One 2011; 6:e17842.
15. Osinde MO, Kaye DK, Kakaire O. Sexual behaviour and HIV sero-discordance among HIV patients receiving HAART in rural Uganda. J Obstet Gynaecol 2011; 31:436-440.
16. Stuart A, Ord JK. Kendall's advanced theory of statistics. London, England: Arnold Publishers; 1994.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
18. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18:321-359.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
22. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items For Systematic Reviews and Meta-Analyses: the PRISMA statement. BMJ 2009; 339:b2535.
25. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet 1999; 353:786-792.
26. Quava-Jones A. Adherence to antiretrovirals during and after pregnancy in women attending an HIV treatment clinic in Trinidad (abstract no. CDC012). In: 5th IAS Conference on HIV Pathogenesis and Treatment. Cape Town, South Africa; 2009.
27. Chaovarindr U, Chalermchokcharoenkit A, Asavapiriyanont S, Sirimai K, Culnane M, Teeraratkul A, et al. Acceptance of and adherence to zidovudine and infant formula for preventing mother-child HIV transmission, Bangkok, Thailand. Symposium Session: The XIV International AIDS Conference, Mexico City, 3-8 August, 2008 [Abstract no. ThOrD1430] http://www. iasociety.org/Default.aspx? pageId¼11&abstractId¼4998 [Accessed 9 July 2011].
28. Chi BH, Chintu N, Cantrell RA, Kankasa C, Kruse G, Mbewe F, et al. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. J Acquir Immune Defic Syndr 2008; 48:220-223.
29. Ciambrone D, Loewenthal HG, Bazerman LB, Zorilla C, Urbina B, Mitty JA. Adherence among women with HIV infection in Puerto Rico: the potential use of modified directly observed therapy (MDOT) among pregnant and postpartum women. Women Health 2006; 44:61-77.
30. Imbaya CL, Odhiambo-Otieno GW, Okello-Agina BM. Adherence levels to antenatal regimens of NVP and AZT among HIVR women receiving PMTCT treatment at Pumwani Maternity Hospital in Nairobi, Kenya. AIDS 2008-The XVII International AIDS Conference, Mexico City, 3-8 August 2008 [Abstract MOPE0519]. http://www.iasociety.org/Abstracts/A200715665.aspx [Accessed 9 July 2011].
31. Laine C, Newschaffer CJ, Zhang D, Cosler L, Hauck WW, Turner BJ. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Obstet Gynecol 2000; 95:167-173.
32. Kingston MA, Letham CJ, McQuillan O. Adherence to anti-retroviral therapy in pregnancy. Int J STD AIDS 2007; 18:787-789.
33. Mellins CA, Chu C, Malee K, Allison S, Smith R, Harris L, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care 2008; 20:958-968.
34. Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008; 48:408-417.
35. Kirsten I, Sewangi J, Kunz A, Dugange F, Ziske J, Jordan-Harder B, et al. Adherence to combination prophylaxis for prevention of mother-to-child- transmission of HIV in Tanzania. PLoS One 2011; 6:e2120.
36. Demas PA, Thea DM, Weedon J, McWayne J, Bamjl M, Lambert G, et al. Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy. Women Health 2005; 42:99-115.
37. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362:2282-2294.
38. Turner BJ, Newschaffer CJ, Hauck WW, Zhang D, Cosler L. Antiretroviral use and adherence in a cohort of 696 HIVR pregnant women (abstract no. 32329). Int Conf AIDS. Geneva, Switzerland; 1998. p. 536.
39. Turner BJ, Newschaffer CJ, Zhang DZ, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care 2000; 38:911-925.
40. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Over-baugh J, John-Stewart GC. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS 2005; 19:1415-1422.
41. Mepham S, Zondi Z, Mbuyazi A, Mkhwanazi N, Newell ML. Challenges in PMTCT antiretroviral adherence in northern KwaZulu-Natal, South Africa. AIDS Care 2011; 23:741-747.
42. Louis JM, Buhari MA, Blackwell SC, Refuerzo J, Allen D, Gonik B, et al. Characteristics associated with suboptimal viral suppression at delivery in human immunodeficiency virus-1-infected pregnant women. Am J Obstet Gynecol 2005; 193:1266-1269.
43. Megazzini KM, Sinkala M, Vermund SH, Redden DT, Krebs DW, Acosta EP, et al. A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia. AIDS 2010; 24:447-455.
44. Stringer JS, Sinkala M, Stout JP, Goldenberg RL, Acosta EP, Chapman V, et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. J Acquir Immune Defic Syndr 2003; 32:506-513.
45. Kiarie JN, Kreiss JK, Richardson BA, John-Stewart GC. Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya. AIDS 2003; 17:65-71.
46. Tedaldi E, Willard S, Gilmore J, Holdsworth C, Dix-Lassiter S, Axelrod P. Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus. J Assoc Nurses AIDS Care 2002; 13:60-65.
47. Conkling M, Shutes EL, Karita E, Chomba E, Tichacek A, Sinkala M, et al. Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study. J Int AIDS Soc 2010; 13:10.
48. Mirkuzie AH, Hinderaker SG, Sisay MM, Moland KM, Morkve O. Current status of medication adherence and infant follow up in the prevention of mother to child HIV transmission programme in Addis Ababa: a cohort study. J Int AIDS Soc 2011; 14:50.
49. Peltzer K, Mlambo M, Phaswana-Mafuya N, Ladzani R. Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa. Acta Paediatr 2010; 99:699-704.
50. Stringer JS, Sinkala M, Maclean CC, Levy J, Kankasa C, Degroot A, et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS 2005; 19:1309-1315.
51. Kesho Bora Study Group. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts. J Acquir Immune Defic Syndr 2010; 54:533-541.
52. Manenti SA, Galato JJ, Silveira ES, Oenning RT, Simoes PW, Moreira J, et al. Epidemiologic and clinical characteristics of pregnant women living with HIV/AIDS in a region of southern Brazil where the subtype C of HIV-1 infection predominates. Braz J Infect Dis 2011; 15:349-355.
53. Peltzer K, Sikwane E, Majaja M. Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa. Acta Paediatr 2011; 100:1253-1257.
54. Peltzer K, Mosala T, Dana P, Fomundam H. Follow-up survey of women who have undergone a prevention of mother-to-child transmission program in a resource-poor setting in South Africa. J Assoc Nurses AIDS Care 2008; 19:450-460.
55. Zorrilla CD, Santiago LE, Knubson D, Liberatore K, Estronza G, Colon O, et al. Greater adherence to highly active antiretro-viral therapy (HAART) between pregnant versus nonpregnant women living with HIV. Cell Mol Biol 2003; 49:1187-1192.
56. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, Kinuthia J, et al. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 RNA: a phase II randomized clinical trial. Antivir Ther 2008; 13:799-807.
57. Vaz MJ, Barros SM, Palacios R, Senise JF, Lunardi L, Amed AM, et al. HIV-infected pregnant women have greater adherence with antiretroviral drugs than nonpregnant women. Int J STD AIDS 2007; 18:28-32.
58. Durante AJ, Bova CA, Fennie KP, Danvers KA, Holness DR, Burgess JD, et al. Home-based study of anti-HIV drug regimen adherence among HIV-infected women: feasibility and preliminary results. AIDS Care 2003; 15:103-115.
59. Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseini-pour MC, Kourtis AP, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362:2271-2281.
60. Shapiro RL, Thior I, Gilbert PB, Lockman S, Wester C, Smeaton LM, et al. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006; 20:1281-1288.
61. Kuonza LR, Tshuma CD, Shambira GN, Tshimanga M. Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study. BMC Public Health 2010; 10:218.
62. Barigye H, Levin J, Maher D, Tindiwegi G, Atuhumuza E, Nakibinge S, et al. Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting. Trop Med Int Health 2010; 15:1163-1171.
63. Albrecht S, Semrau K, Kasonde P, Sinkala M, Kankasa C, Vwalika C, et al. Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission. J Acquir Immune Defic Syndr 2006; 41:114-118.
64. Ickovics JR, Wilson TE, Royce RA, Minkoff HL, Fernandez MI, Fox-Tierney R, et al. Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS substudy from the Perinatal Guidelines Evaluation Project. J Acquir Immune Defic Syndr 2002; 30:311-315.
65. Cohn SE, Umbleja T, Mrus J, Bardeguez AD, Andersen JW, Chesney MA. Prior illicit drug use and missed prenatal vitamins predict nonadherence to antiretroviral therapy in pregnancy: adherence analysis A5084. AIDS Patient Care STDS 2008; 22:29-40.
66. Bii SC, Otieno-Nyunya B, Siika A, Rotich JK. Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital. East Afr Med J 2007; 84:571-576.
67. Wilson TE, Ickovics JR, Fernandez MI, Koenig LJ, Walter E. Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. Am J Obstet Gynecol 2001; 184:1235-1240.
68. Wiktor SZ, Ekpini E, Karon JM, Nkengasong J, Maurice C, Severin ST, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353:781-785.
69. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353:773-780.
70. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351:217-228.
71. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11:171-180.
72. Thomas TK, Masaba R, Borkowf CB, Ndivo R, Zeh C, Misore A, et al. Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding: the Kisumu Breastfeeding Study, Kenya-a clinical trial. PLoS Med 2011; 8:e1001015.
73. Caswell RJ, Phillips D, Chaponda M, Khoo SH, Taylor GP, Ghanem M, et al. Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir. Int J STD AIDS 2011; 22:11-14.
74. Stringer EM, Ekouevi DK, Coetzee D, Tih PM, Creek TL, Stinson K, et al. Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries. JAMA 2010; 304:293-302.
75. Leisegang R, Nachega JB, Hislop M, Maartens G. The impact of pregnancy on adherence to and default from ART. In: 18th Conference on Retroviruses and Opportunistic Infections; 2011.
76. Puskas CM, Forrest JI, Parashar S, Salters KA, Cescon AM, Kaida A, et al. Women and vulnerability to HAART non-adherence: a literature review of treatment adherence by gender from 2000 to 2011. Curr HIV/AIDS Rep 2011; 8:277-287.
77. Merenstein D, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association of child care burden and household composition with adherence to highly active antiretro-viral therapy in the Women's Interagency HIV Study. AIDS Patient Care STDS 2009; 23:289-296.
78. Merenstein DJ, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study. Pediatrics 2008; 121:e787-e793.
79. ACOG (American College of Obstetrics and Gynecology). Practice Bulletin: nausea and vomiting of pregnancy. Obstet Gynecol 2004; 103:803-814.
80. Breese McCoy SJ. Postpartum depression: an essential overview for the practitioner. South Med J 2011; 104:128-132.
81. Villegas L, McKay K, Dennis CL, Ross LE. Postpartum depression among rural women from developed and developing countries: a systematic review. J Rural Health 2011; 27:278-288.
82. Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med 2006; 3:e438.
83. Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med 2009; 6:e11.
84. Stoff DM, Mitnick L, Kalichman S. Research issues in the multiple diagnoses of HIV/AIDS, mental illness and substance abuse. AIDS Care 2004; 16 (Suppl 1):S1-S5.
85. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817-833.
86. Zachariah R, Ford N, Philips M, Lynch S, Massaquoi M, Janssens V, et al. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Trans R Soc Trop Med Hyg 2009; 103:549-558.
87. Shetty AK, Marangwanda C, Stranix-Chibanda L, Chandisarewa W, Chirapa E, Mahomva A, et al. The feasibility of preventing mother-to-child transmission of HIV using peer counselors in Zimbabwe. AIDS Res Ther 2008; 5:17.
88. Baek C, Mathambo V, Mkhize S, Friedman I, Apicella L, Rutenberg N. Key findings from an evaluation of the mothers2mothers program in KwaZulu-Natal, South Africa. New York: Horizons Program & Health Systems Trust; 2007.
89. Zuyderduin JR, Ehlers VJ, Van der Wal D. The impact of a buddy system on the self-care behaviours of women living with HIV/AIDS in Botswana. Health SA Gesondheid 2008; 13:4-15.
90. Rotheram-Borus MJ, Richter L, Van Rooyen H, van Heerden A, Tomlinson M, Stein A, et al. Project Masihambisane Protocol: a cluster randomised controlled trial with peer mentors to improve outcomes for pregnant mothers living with HIV. Trials 2011; 12:2.
91. McCabe CJ, Goldie SJ, Fisman DN. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women. PLoS One 2010; 5:e10154.
92. Peltzer K, Jones D, Weiss SM, Shikwane E. Promoting male involvement to improve PMTCT uptake and reduce antenatal HIV infection: a cluster randomized controlled trial protocol. BMC Public Health 2011; 11:778.
93. Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:1069-1076.
94. Zeh C, Weidle PJ, NafisaL, Lwamba HM, OkonjiJ, Anyango E, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
95. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 2011; 5:357-367.
96. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006; 333:597-600.
97. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ 2008; 336:1413-1415.
98. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14:731-747.
99. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-690.
100. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-1573.
101. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 2002; 55:86-94.